Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009

Kucharzik, T.; Dignass, A.; Atreya, R.; Bokemeyer, B.; Esters, P.; Herrlinger, K.; Kannengiesser, K.; Kienle, P.; Langhorst, J.; Lügering, A.; Schreiber, S.; Stallmach, A.; Stein, J.; Sturm, A.; Teich, N.; Siegmund, B.; ,

doi:10.1055/a-2060-0935

Cited by 13 publications

(1 citation statement)

References 833 publications

(1,203 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Probiotics, live bacteria believed to promote health, have been recognized for their beneficial effects for many decades in different indications. The use of the probiotic Escherichia coli (E. coli) Nissle 1917 is recommended in guidelines for patients with ulcerative colitis ( 78 ). A pilot study by an Italian group demonstrated that the intake of various probiotics over 8 weeks led to a modification of well-being status, as well as inflammatory and oxidative indexes in CFS/ME patients, resulting in a reduction of inflammatory parameters after probiotic intake ( 13 )( Table 1 ).…”

Section: Modulation Of the Gastrointestinal Microbiome As Rational Th...mentioning

confidence: 99%

The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives

Stallmach,

Quickert,

Puta

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Like other infections, a SARS-CoV-2 infection can also trigger Post-Acute Infection Syndromes (PAIS), which often progress into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). ME/CFS, characterized by post-exercise malaise (PEM), is a severe multisystemic disease for which specific diagnostic markers or therapeutic concepts have not been established. Despite numerous indications of post-infectious neurological, immunological, endocrinal, and metabolic deviations, the exact causes and pathophysiology remain unclear. To date, there is a paucity of data, that changes in the composition and function of the gastrointestinal microbiota have emerged as a potential influencing variable associated with immunological and inflammatory pathways, shifts in ME/CFS. It is postulated that this dysbiosis may lead to intestinal barrier dysfunction, translocation of microbial components with increased oxidative stress, and the development or progression of ME/CFS. In this review, we detailed discuss the findings regarding alterations in the gastrointestinal microbiota and its microbial mediators in ME/CFS. When viewed critically, there is currently no evidence indicating causality between changes in the microbiota and the development of ME/CFS. Most studies describe associations within poorly defined patient populations, often combining various clinical presentations, such as irritable bowel syndrome and fatigue associated with ME/CFS. Nevertheless, drawing on analogies with other gastrointestinal diseases, there is potential to develop strategies aimed at modulating the gut microbiota and/or its metabolites as potential treatments for ME/CFS and other PAIS. These strategies should be further investigated in clinical trials.

show abstract

Section: Modulation Of the Gastrointestinal Microbiome As Rational Th...mentioning

confidence: 99%